Neoclomide 1 gm/vial (IV Infusion)
1 gm vial: ৳ 800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Cyclophosphamide |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Malignant lymphomas
- Hodgkin's disease
- Leukemias
- Mycosis fungoides
- Neuroblastoma
- Adenocarcinoma of the ovary
- Retinoblastoma
- Carcinoma of the breast
- Minimal Change Nephrotic Syndrome
Pharmacology
- Biotransformation in liver
- Active alkylating metabolites
- Interfere with growth of malignant cells
- Cross-linking of tumor cell DNA
- High bioavailability after oral administration
- Elimination in urine
- Plasma protein binding
- Metabolites in plasma and urine
Dosage & Administration
- Intravenous administration
- 40-50 mg/kg initial dose
- Oral dosing range of 1-5 mg/kg/day
- Dosage adjustment based on leukocyte count
- Dialyzable
- No consistent evidence for renal impairment dosage modification
- Specific dosage for Minimal Change Nephrotic Syndrome in children
Interaction
- Metabolism and leukopenic activity affected by phenobarbital
- Possible combined drug actions
- Inhibition of cholinesterase activity potentiation
- Alerting anesthesiologist after Neoclomide treatment
Contraindications
- Severely depressed bone marrow function
- Previous hypersensitivity
Side Effects
- Nausea and vomiting
- Anorexia
- Abdominal discomfort
- Diarrhea
- Hemorrhagic colitis
- Alopecia
- Skin rash
- Leukopenia
- Thrombocytopenia
- Anemia
- Hemorrhagic ureteritis
- Renal tubular necrosis
- Interstitial pneumonitis
- Anaphylactic reactions
- SIADH
- Malaise and asthenia
Pregnancy & Lactation
- Pregnancy Category D
- Excretion in breast milk
- Consideration for discontinuing nursing
Precautions & Warnings
- Special attention in presence of certain conditions
- Leukopenia
- Thrombocytopenia
- Tumor cell infiltration of bone marrow
- Impaired hepatic function
- Impaired renal function
Use in Special Populations
- Similar safety profile in pediatric patients
- Insufficient data for patients aged 65 and older
- Increased susceptibility of elderly to toxicities
Overdose Effects
- No specific antidote
- Supportive measures for managing overdose
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Temperature not exceeding 25°C
- Dry place
- Protected from light and moisture
- No freezing